Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2

Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response

(2018) Sabine Hombach-Klonisch et al.   PHARMACOLOGY & THERAPEUTICS

A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma

(2018) Xiaoyue Chen et al.   Nature Communications

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

(2017) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

(2017) Michael Weller et al.   LANCET ONCOLOGY

Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications

(2017) Alba A. Brandes et al.   ONCOLOGIST

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

DNA Repair Capacity in Multiple Pathways Predicts Chemoresistance in Glioblastoma Multiforme

(2016) Zachary D. Nagel et al.   CANCER RESEARCH

Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line

(2016) Guo-zhong Yi et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Advances in the molecular genetics of gliomas — implications for classification and therapy

(2016) Guido Reifenberger et al.   Nature Reviews Clinical Oncology

Differential propagation of stroma and cancer stem cells dictates tumorigenesis and multipotency

(2016) J Behnan et al.   ONCOGENE

WDR76 Co-Localizes with Heterochromatin Related Proteins and Rapidly Responds to DNA Damage

(2016) Joshua M. Gilmore et al.   PLoS One

Expression of dynein, cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma cell resistance to temozolomide

(2016) Hai Wang et al.   Scientific Reports

MIR517Cinhibits autophagy and the epithelial-to-mesenchymal (-like) transition phenotype in human glioblastoma through KPNA2-dependent disruption of TP53 nuclear translocation

(2015) Yuntao Lu et al.   Autophagy

XPC: Going where no DNA damage sensor has gone before

(2015) Leah Nemzow et al.   DNA REPAIR

Ubiquitin-specific Protease 7 Regulates Nucleotide Excision Repair through Deubiquitinating XPC Protein and Preventing XPC Protein from Undergoing Ultraviolet Light-induced and VCP/p97 Protein-regulated Proteolysis

(2014) Jinshan He et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

ATM Regulates 3-Methylpurine-DNA Glycosylase and Promotes Therapeutic Resistance to Alkylating Agents

(2014) S. Agnihotri et al.   Cancer Discovery

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

Differential contribution of HP1 proteins to DNA end resection and homology-directed repair

(2013) Gaston Soria et al.   CELL CYCLE

HP1 promotes tumor suppressor BRCA1 functions during the DNA damage response

(2013) Young-Ho Lee et al.   NUCLEIC ACIDS RESEARCH

Recombinant human cytoplasmic dynein heavy chain 1 and 2: Observation of dynein-2 motor activity in vitro

(2011) Muneyoshi Ichikawa et al.   FEBS LETTERS

HP1α recruitment to DNA damage by p150CAF-1 promotes homologous recombination repair

(2011) Céline Baldeyron et al.   JOURNAL OF CELL BIOLOGY

Complex interactions between genes controlling trafficking in primary cilia

(2011) Polloneal Jymmiel R Ocbina et al.   NATURE GENETICS

Lamin A Rod Domain Mutants Target Heterochromatin Protein 1α and β for Proteasomal Degradation by Activation of F-Box Protein, FBXW10

(2010) Pankaj Chaturvedi et al.   PLoS One

XPC Silencing Sensitizes Glioma Cells to Arsenic Trioxide via Increased Oxidative Damage

(2010) Shin-Yi Liu et al.   TOXICOLOGICAL SCIENCES

DYNC2H1 Mutations Cause Asphyxiating Thoracic Dystrophy and Short Rib-Polydactyly Syndrome, Type III

(2009) Nathalie Dagoneau et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Glioma Stem Cell Lines Expanded in Adherent Culture Have Tumor-Specific Phenotypes and Are Suitable for Chemical and Genetic Screens

(2009) Steven M. Pollard et al.   Cell Stem Cell

Recruitment of heterochromatin protein 1 to DNA repair sites

(2009) Miroslaw Zarebski et al.   CYTOMETRY PART A

Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma

(2009) Jennifer A. Quinn et al.   JOURNAL OF CLINICAL ONCOLOGY

The Emerging Role of HP1 in the DNA Damage Response

(2009) C. Dinant et al.   MOLECULAR AND CELLULAR BIOLOGY

Two-Step Recognition of DNA Damage for Mammalian Nucleotide Excision Repair: Directional Binding of the XPC Complex and DNA Strand Scanning

(2009) Kaoru Sugasawa et al.   MOLECULAR CELL

JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin

(2009) Mark A. Dawson et al.   NATURE

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

Temozolomide and carmustine cause large-scale heterochromatin reorganization in glioma cells

(2008) Roberto Papait et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

A New Model for Prediction of Drug Distribution in Tumor and Normal Tissues: Pharmacokinetics of Temozolomide in Glioma Patients

(2008) L. Rosso et al.   CANCER RESEARCH

Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma

(2008) J. N. Sarkaria et al.   CLINICAL CANCER RESEARCH

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE